- Genset has announced its public offering of 1.8 million ordinary shares/American Depositary Shares. Each ADS is equivalent to one-third of one ordinary share at a cost of $16 per ADS. All shares are to be sold by the company. It has granted the underwriters the option to buy 270,000 additional ordinary shares. Proceeds will be used for R&D and corporate expenses.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze